Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox

Corral, Javier; Roldán, Vanessa; Vicente, Vicente

doi:10.3324/haematol.2010.023432

Cited by 29 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, we showed that the risk increased with the degree of obesity, and was also increased for unprovoked or provoked VT, for deep vein thrombosis, and in both men and women. We observed little effect of FV Leiden on PE risk (also known as the FV Leiden paradox) when combined with increasing BMI and/or blood group non‐O . This results adds credence to the hypothesis that APC resistance (present in FV Leiden carriers and in individuals with high BMI) preferentially affects the risk of deep vein thrombosis and not of PE.…”

Section: Resultssupporting

confidence: 70%

Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors

Ribeiro

Lijfering

Rosendaal

et al. 2016

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

To cite this article: Ribeiro DD, Lijfering WM, Rosendaal FR, Cannegieter SC. Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors. J Thromb Haemost 2016; 14:1572-8. Essentials • Obesity, factor V Leiden (FVL) and blood group non-O are common. • We studied the combined effect of these factors on the risk of venous thrombosis (VT). • The combination of obesity, non-O blood group and FVL increased VT risk up to tenfold. • Identifying high VT may be beneficial in thrombosis prevention. Summary. Background: Overweight/obesity has a substantial effect on the occurrence of venous thrombosis (VT). Blood group non-O has a high prevalence in Western populations, and the factor V Leiden mutation could be present in 5% of Caucasians. These frequent prothrom-botic risk factors will have a considerable impact on the incidence of VT, especially when combined. Objectives: We investigated whether FV Leiden with blood group non-O modifies VT risk in individuals with different body mass index (BMI) strata in a case-control study (n = 11253). Results: We observed a progressively increasing risk of VT with higher BMI, with an odds ratio of 1.9 (95% confidence interval [CI] 1.6-2.3) for those in the upper BMI tertile (BMI > 26.7 kg m À2), as compared with the first BMI tertile (BMI < 23.5 kg m À2 , blood group O, and no FV Leiden) (reference group). The addition of FV Leiden and blood group non-O to the model increased the risk in all BMI tertiles; the odds ratios were 3.8 (95% CI 3.2-4.6) in the third BMI tertile of individuals with blood group non-O, and 5.4 (95% CI 3.5-8.5) in the third BMI tertile of individuals with FV Leiden. When both FV Leiden and blood group non-O were present , the odds ratios were 9.1 (95% CI 5.9-14.0) in the first BMI tertile, 9.4 (95% CI 6.6-13.5) in the second BMI tertile, and 12.5 (95% CI 8.9-17.6) in the third BMI tertile. Conclusion: Individuals with a high BMI, blood group non-O and/or FV Leiden have a high VT risk. The high VT risks in some subgroups may justify targeted screening and thromboprophylaxis decisions in these patients.

show abstract

Section: Resultssupporting

confidence: 70%

Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors

Ribeiro

Lijfering

Rosendaal

et al. 2016

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

show abstract

“…The genetic risk difference between DVT and PE appears to follow the same pattern as has been previously described for FVL. 39 We observed that the presence of F5 rs4524 had a particularly strong impact on the incidence of VTE during the first 6 months after the diagnosis of cancer.…”

Section: Discussionmentioning

confidence: 80%

Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism

et al. 2016

View full text Add to dashboard Cite

“…The carriers of FVL mutant proteins confer a greater risk of developing deep vein thrombosis compared with normal individuals (25). Further, the carriers of prothrombin G20210A mutation are associated with a 3-fold greater risk of venous thrombosis (26).…”

Section: Discussionmentioning

confidence: 99%

Factor V Leiden and prothrombin G20210A mutations and risk of vaso-occlusive complications in sickle cell disease: A meta-analysis through the lens of nephrology

Bhaskar¹

2019

J Nephropharmacol

View full text Add to dashboard Cite

Hemolysis is a fundamental feature that contributes to hypercoagulability and thrombotic complications in sickle cell disease (SCD). Factor V Leiden (FVL) and prothrombin G20210A mutations are the most common genetic thrombophilia. Objectives: The aim of this meta-analysis is to determine the relationship between FVL or prothrombin G20210A and susceptibility of vaso-occlusive complications (VOC) in SCD. Patients and Methods: For this meta-analysis, eligible studies were retrieved via two systematic searches performed on PubMed, Web of Science and Google Scholar databases. The keywords used in the former search included 'sickle cell anemia' , 'SCD' , 'Factor V Leiden' and 'G1691A (rs6025) mutation, the letter using the keywords 'sickle cell anemia' , 'SCD' , 'prothrombin, and 'G20210A (rs1799963). Results: The final number of studies included was 10 about SCD-VOC and FVL (total patients with VOC 1086 and without VOC 933), and 6 about SCD-VOC and prothrombin G20210A mutation (total patients with VOC 609 and without VOC 674). Meta-analysis in fixed effect model showed that mutant genotypes (GA+AA vs. GG) of the FVL mutation was found to be higher in SCD patients with VOC than in SCD patients without VOC (OR, 3.53; 95% CI, 2.24-5.08; P < 0.001). However, the distribution of prothrombin G20210A mutation in SCD patients with or without VOC is similar (OR, 0.900; 95% CI, 0.51-1.59; P = 0.717). Conclusion: Our meta-analysis establishes that the FVL mutation as a high-penetrant risk factor for VOC in SCD patients, whereas the prothrombin G20210A is not associated with the risk of VOC in SCD patients. To further validate the clinical utility of these prothrombotic mutations in SCD patient, large scale and prospective studies in diverse populations are warranted.

show abstract

Deep venous thrombosis or pulmonary embolism and factor V Leiden: enigma or paradox

Cited by 29 publications

References 35 publications

Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors

Risk of venous thrombosis in persons with increased body mass index and interactions with other genetic and acquired risk factors

Joint effects of cancer and variants in the factor 5 gene on the risk of venous thromboembolism

Factor V Leiden and prothrombin G20210A mutations and risk of vaso-occlusive complications in sickle cell disease: A meta-analysis through the lens of nephrology

Contact Info

Product

Resources

About